Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Melanoma 91Carcinoma, Non-Small-Cell Lung 84Neoplasms 48Carcinoma, Renal Cell 44Neoplasm Metastasis 41Squamous Cell Carcinoma of Head and Neck 36Carcinoma, Hepatocellular 36Colorectal Neoplasms 31Pancreatic Neoplasms 24Lung Neoplasms 20Stomach Neoplasms 19Head and Neck Neoplasms 18Carcinoma, Transitional Cell 17Hodgkin Disease 16Breast Neoplasms 16Small Cell Lung Carcinoma 15Ovarian Neoplasms 14Urinary Bladder Neoplasms 13Recurrence 13Advanced Cancer 13Glioblastoma 12Brain Neoplasms 12Lymphoma 11Kidney Neoplasms 11Glioma 11Prostatic Neoplasms 10Lymphoma, Non-Hodgkin 10Uveal Melanoma 9Triple Negative Breast Neoplasms 9Sarcoma 9

Interventions

rucaparib 1fludarabine 1Sunitinib 1Stem Cell Transplantation 1Sirolimus 1Radiotherapy 1Paclitaxel 1Nivolumab 1Melphalan 1Erlotinib Hydrochloride 1Carboplatin 1Busulfan 1Bevacizumab 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma, Clear Cell × Nivolumab × Clear all
NCT03241745 2024-12-27

A Study of Nivolumab in Selected Uterine Cancer Patients

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
35 enrolled 8 charts
GynecologicSarcoma

Carcinosarcoma, Leiomyosarcoma, Uterine Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡